Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 07, 2023

SELL
$0.57 - $0.88 $104,365 - $161,126
-183,098 Reduced 17.41%
868,620 $754,000
Q1 2023

May 11, 2023

SELL
$0.61 - $1.03 $24,789 - $41,857
-40,638 Reduced 3.72%
1,051,718 $733,000
Q4 2022

Feb 14, 2023

BUY
$0.62 - $1.21 $118,746 - $231,747
191,527 Added 21.26%
1,092,356 $894,000
Q3 2022

Nov 14, 2022

BUY
$1.05 - $2.1 $601,879 - $1.2 Million
573,219 Added 174.97%
900,829 $936,000
Q3 2022

Nov 14, 2022

BUY
$1.05 - $2.1 $601,879 - $1.2 Million
573,219 Added 174.97%
900,829 $936,000
Q2 2022

Aug 09, 2022

BUY
$1.42 - $3.15 $152,483 - $338,256
107,383 Added 48.76%
327,610 $537,000
Q1 2022

May 12, 2022

BUY
$2.65 - $5.08 $151,084 - $289,626
57,013 Added 34.93%
220,227 $646,000
Q4 2021

Feb 10, 2022

BUY
$4.73 - $7.9 $772,002 - $1.29 Million
163,214 New
163,214 $778,000
Q2 2021

Aug 11, 2021

SELL
$6.45 - $9.09 $3.74 Million - $5.27 Million
-579,677 Closed
0 $0
Q1 2021

May 11, 2021

BUY
$7.25 - $13.82 $1.19 Million - $2.26 Million
163,582 Added 39.31%
579,677 $4.52 Million
Q4 2020

Feb 11, 2021

BUY
$6.87 - $10.48 $150,198 - $229,124
21,863 Added 5.55%
416,095 $3.84 Million
Q3 2020

Nov 09, 2020

BUY
$5.06 - $7.23 $745,383 - $1.07 Million
147,309 Added 59.66%
394,232 $2.72 Million
Q2 2020

Aug 12, 2020

BUY
$1.57 - $6.56 $177,849 - $743,116
113,280 Added 84.76%
246,923 $1.62 Million
Q1 2020

May 11, 2020

BUY
$1.44 - $3.95 $38,594 - $105,867
26,802 Added 25.09%
133,643 $251,000
Q3 2019

Nov 07, 2019

BUY
$1.4 - $2.84 $9,409 - $19,087
6,721 Added 6.71%
106,841 $151,000
Q2 2019

Aug 08, 2019

BUY
$2.75 - $4.89 $21,010 - $37,359
7,640 Added 8.26%
100,120 $283,000
Q1 2019

May 09, 2019

BUY
$4.11 - $5.88 $325,310 - $465,407
79,151 Added 593.83%
92,480 $441,000
Q4 2018

Feb 07, 2019

BUY
$3.65 - $10.69 $48,650 - $142,487
13,329 New
13,329 $56,000

Others Institutions Holding SURF

About Surface Oncology, Inc.


  • Ticker SURF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,034,000
  • Description
  • Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...
More about SURF
Track This Portfolio

Track Acadian Asset Management LLC Portfolio

Follow Acadian Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.